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1. Introduction 
Although herbal/natural remedies have been, and are still being used, in the treatment of 
chronic degenerative diseases, little is known about basic principles –or theory- to combine 
these components and attain synergistic, gene modulating, as well as clinical health 
improving effects. This chapter is divided into six sections. Section 2 reviews the 
background which gives origin and establishes the Systemic Theory and Systemic Medicine. 
The section also provides the general precepts to structure Circulat -a complex herbal 
formulation- for the treatment of circulatory chronic degenerative diseases. Section 3 is an 
outline of an investigation into the aforementioned formulation’s role and capability to 
modulate various gene expression levels -in cultured human fibroblasts- including those 
associated with diabetes. On the other hand, Section 4 presents a review of Circulat´s clinical 
properties through a Diabetic Foot management Study. An abbreviated limited Phase 2 
GSPECT evaluated Chronic Ischemic Disease –another circulatory chronic disease- study is 
presented in Section 5. Finally, Section 6 provides some conclusions concerning the use of a 
complex herbal formulation as well as some reflections on the future design of such 
compositions. 
2. The origin of Systemic theory and Systemic medicine: Relevance to 
complementary and alternative medicine  
Past and Present Phytomedicine and natural practitioners: Tomorrow’s Systemics? Recent 
past -and even present- successful phytomedicine practitioners and naturalists share a 
long and honorable tradition of knowledge and pride in the cure of illnesses, which goes 
back to written history and beyond. These qualities have been substantiated by the 
successes of the Chinese (Chen et al., 2004; Wago & Deng, 2004), Kampo (Teresawa, 2004; 
Yamada, 2004), Ayurvedic (Naik et al., 2003), Chumash (Adams and Garcia, 2005) or 
Mayan (Peña, 2002) traditional medicines among many others. These traditional 
medicines ‘demonstrated that every culture is capable of understanding and “inventing” 
the meaning of disease and its cure, even when it is different from our modern medical 
views’ (Peña, 2002). The variability and extent of cultures to provide answers -or 
traditional medicines- to pathologies are embedded in the curiosity and observational 
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capabilities of the human race. There are also collective factors such as ‘a background of 
extensive family in traditional medicine’ (Vandenbroek et al., 2004) which play an 
important role in the communication and survival of medicinal plant knowledge among 
ethnic groups. A potential issue, though, is the possible curtailment of the wisdom -and 
therapies- of traditional medicines within geographical and ethnic boundaries. In any 
case, the amount of plants, potential formulations or properties are a massive concern for 
any given individual caregiver or group to understand, store and transmit. Some 
exceptional individuals seem to have come by this ability. One of these gifted health care 
practitioners was Maurice Messegue, whom Mistinguet and Konrad Adenaur -among his 
famous patients- swore that only he could treat their illnesses. More recently, both, Dr. 
Rusudan Lomidze, using the Georgian Kohlkian traditional medicine, and Lonrig Dangar, 
a Tibetan physician who applied the rich Tibetan traditional medicine have also obtained 
significant success. These gifted individuals have shown that traditional medicine is a 
successful medicine. But a question still hangs in the air. Might a theory be devised by 
which regular practitioners, health care specialists devoid of the naturalists’ extensive 
background, formulate natural organic therapeutic protocols? Furthermore, is it possible 
to set up a system -or periodic table- where plants and other natural remedies could, 
according to superior therapeutic properties, be arranged to produce specific formulae 
that provide well-being for a given pathology? The treatment of circulatory pathologies 
with substances which act only on function and structure might be an incomplete 
approach. Whether the investigations in circulatory chronic disease studies –and their 
results- can be generalized in confirmation of a systemic approach is something that 
should be pursued as this may pave the way for a new integral vision of therapeutics in 
general and/or in circulatory chronic diseases such as Diabetes in particular.  
2.1 Prior developments of a natural therapeutic protocol: Systemic Theory 
Aggressors or stressors were identified by Professor Hans Selye, and described and 
classified in over 1500 articles and 32 books. He formulated the General Adaptation 
Syndrome (Selye, 1976), which classified effects on animals and humans affected by threats 
(exhaustion, disease, fear, extreme cold …) as: alarm (body’s recognition of danger and its 
preparation to deal with threats); resistance (or adaptation, in which the body adapts to 
resist stress); and exhaustion (condition in which the body’s energy supply is depleted). The 
next step was taken by Soviet scientists led by Lazarev and Brekhman, who investigated 
properties of substances, with the ability to increase adaptability and resistance to stress. 
They named these ‘adaptogens’. By 1960 more than 1000 studies had been published by 
Soviet scientists concerning the use of adaptogens. In 1962, Eleutherococcus senticosus, 
Rhaponticum carthamoides and Rhodiola rosea, all adaptogens, were included in the Soviet 
Union’s Pharmacopoeia. Since then many other plants and sources have been found to have 
similar properties (Brekman and Ivanov, 1969; Khasina et al., 1983; Bhattacharya and 
Muruganandam, 2003; Dhuley, 2000) and increasing resistance to stressors as depicted by 
Selye, enhancing energy, and regulating immune, neuroendocrine and cellular function. 
Although the adaptogen definition in science is questioned by some researchers, most 
concur on their health enhancing properties (Davydov and Krikorian, 2000). Figure 1 
(Olalde, 2005a) is an interpretation of Energy drop (EŅ) in relation to Selye’s description of 
biochemical collapse (IŅ) and organic dysfunction (OŅ). This paved the way to the E, I and O 
triangle. 
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Fig. 1. Functional energy reserve ladder. Energy drop affects the human organism, going 
from a state of well being with high Energy reserves and low entropy - low disorder- 
through various stages and finally to that of death, or state of zero energy and maximun 
disorder 
2.1.1 Life and negentropy: Rationalization for the use of phytomedicines 
The second law of thermodynamics states that a system logically tends to go from a state of 
higher energy and order to one of lower energy and disorder. This is more so in living 
systems where internal entropy tends to increase in its journey through life, going from 
health, energy and physiological order towards sickness, asthenia (the loss or lack of bodily 
strength; weakness) and physiological disorder. Illness, however, can be countered based on 
quantum physicist’s Erwin Schrödinger’s notion that the general change of entropy in an 
open system, such as a living (biological) system, consists of (i) internal entropy variations 
and (ii) entropy exchange of the system with the environment; i.e. S = S internal + S 
exchange. Internal entropy in a biological organism, by definition, tends to be greater than 
zero due to inner irreversible processes. Therefore, the increase in entropy of an open 
biological system, and thus illness, may be reduced (von Stockar and Liu, 1999) by 
providing negative entropy –or negentropy- from the environment. This is pivotal as nature 
provides a source of negative entropy. ‘… The decrease of entropy in living systems is 
provided by free energy, released when nutrients consumed from the outside dissociate, i.e. 
at the expense of the sun’s energy. Thus, the flow of negative entropy is essential to 
compensate for inner destructive processes as well as for the decrease of available free 
energy dissipated by spontaneous metabolic reactions. This last, is the key point, circulation 
and transformation of free energy, which drives the functions of living systems …’ 
(Korotkov et al., 2004).  
2.2 ↑ Health ļ entropy Ļ 
How does life defy entropy? In physics, entropy is defined as the measure of disorder in a 
system. Disorder, in turn, can be mathematically expressed by the probability of random 
occurrence. All pathologies, by definition, result from a higher than normal organic entropy; 
thus, to induce health, entropy must first be reduced; this is bi-conditional. Contemporary 
thermodynamics defines entropy (or chaos) in an intelligent system as a deficiency in energy 
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and/or information. Therefore, entropy is inversely related to information and energy 
availability. According to Shannon -father of the Information Theory- and Weaver  
‘information is always a measure of the decrease of uncertainty at a receiver or molecular 
machine’ (Shanon and Weaver, 1999). Thus was born the concept of informational entropy, 
which they concluded was equivalent to a shortage of information content in a message. 
About the same time, Weiner (Weiner, 1954) established the possibility of interpreting 
information carried by a message as ‘… essentially the negative entropy, and the negative 
logarithm of its probability’ since ‘the relationship between information (J) and 
thermodynamic entropy (S) is constant (S + J = const)’ (Korotkov, 1988). Thus, the work of 
such eminent minds as: Boltzmann (Lindley, 2001), Gibbs (Deltete, 1995), Szilard (Leff & 
Rex, 1990), Von Neumann (Heims et al., 1980), Schrödinger (1992), Prigogine (1984), 
Shannon and Weaver (1999) and Weiner (Heims et al., 1980; Weiner, 1954), brought about 
the dawn of new emergent fields, including: informational thermodynamics, information 
theory, biological information theory and cybernetics all dealing with energy, information 
and entropy in mechanical and living systems. A basic common premise in the new thinking 
proposes that information and energy had an inverse, i.e. opposite, correlation with entropy. 
In other words, evidence suggests that no suitable organization can be attained in living 
systems that possess reduced levels of information or energy. Disease, therefore, may be 
defined as a state of disorganization, i.e. higher organic entropy, corresponding with a low 
energo-informational status of the system. In consequence, if a reduction in illness is to be 
achieved, entropy must be reduced. A comprehensive way of accomplishing this, is 
administering negative entropy, or order, through matter which stimulates the production 
of energy and provides survival information to the immune, neuroendorine and cellular 
systems. To recap, the tendency to reach order depends on the energy and information 
available within the system, which determines the possible level of stable organization 
possible. The quantity of true information (conceptual data, not noise) transferred to the 
system’s modulating intelligence allows for chaos and/or confusion management and, 
enhances the system’s ability to attain a higher organization level. Moreover by definition, 
only an intelligent system can process information and energy to reduce entropy. This 
unequivocal fact demonstrates the existence of a regulating biological intelligence within the 
human body. Intelligence is the way in which life affronts entropy. 
2.2.1 The E, I and O health triangle 
All living systems are functional units that seek maximum survival. The cell is the simplest 
form of a living system that functions as a basic building block of the living universe, just as 
an atom does in matter. Conversely, a virus is the simplest living unit, which in some 
situations acts as destroyer of living systems. I (or Intelligence) is the backbone of every 
living system in equilibrium. I controls, regulates, adapts and develops the living system. 
Chaos occurs in its absence. The proof of this is that no living system can exist without 
intelligence. The intelligence of the system, I, creates and utilizes E (or Energy) with the 
primary role of achieving O (Organization) and evolving into a higher system (Owens and 
Van de Castle, 2004). I also creates/builds O with the primary end of producing E. There 
can be a corollary: as a consequence, I cannot act optimally when subjected to a severe 
deficiency of E. Finally, I is the most important side of the health triangle since it 
concurrently generates both energy (E) and organization (O). One phytoceutical that can 
increase all sides is Panax ginseng (Figure 2). 
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Fig. 2. (a) Example of a living system’s health triangle. (b) Evolution from a given health 
situation  and initial E, I, O triangle (left) to an improved E, I, O triangle (right). All sides are 
boosted due to negative entropy provided by Panax ginseng. 
2.2.2 Example of I, E and O increase by providing Panax ginseng 
Panax ginseng active principles are bonded to beta-adrenoceptors in the cellular membrane, 
triggering a secondary transmitting message system (cyclic AMP) which travels through a 
transducer pathway to the mitochondria to increase MDH, SDH and CTS activity, enzymes 
of the glycolisis or tricarboxylic acid cycle. ATP generation is thus increased, raising energy 
levels using glucose as fuel (Figure 3a). Thus, either the ATP/ADP ratio increase or the 
binding of ginsenosides to cell membrane receptors results in the KATP channel closure and 
insulin secretion (Rotsheyn & Zito, 2004) (Figure 3b). Thus with the increase of energy a 
larger health triangle is obtained and the system’s intelligence has acquired more capacity to 
organize. Panax ginseng provides an example of a remarkable phytomedicine which is 
capable of enhancing I, E and O simultaneously in the living system.  
2.3 Significance of the intelligence (I) within the systemic triangle. What is 
intelligence? 
The importance (and significance) of a system’s intelligence is pivotal. How can this 
controversial and subjective concept be defined accurately? Olalde (2005a) confronted this 
dilemma by examining its definition in different fields. Table 1 lists different concepts of the 
term intelligence. 
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Fig. 3. a: (top) Panax intracellular action mechanism results in ATP synthesis stimulation, 
whose hydrolysis produces energy; b: (bottom) shows the Sodium–potassium ATP pump, 
illustrating ATP generation by administering ginsenosides in Panax ginseng to the Living 
System. 
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Domain Reference Definition of intelligence 
Cybernetics Wiener, 1954 
That whose core concepts are communication, 
control and learning, by means of feedback 
mechanisms. 
Physics  Refers to regulation processes. 
Biophysics  
Living system’s endogenous regulation processes 
effectively constitute intelligence. 
Encyclopedic  
Neufeldt V,  
Guralnik D 
(Eds) 
Webster’s New 
World 
Dictionary(1988) 
(a) Ability to learn or understand from experience. 
(b) Ability to acquire and retain knowledge.  
(c) Ability to respond quickly and successfully to a 
new situation. (d) Use of the faculty of reason in 
resolving problems, directing conduct, etc. 
effectively. (e) An intelligent spirit or being.  
(f) Having knowledge, understanding or awareness. 
Multivarious 
World Wide 
Web 
a) Ability of a system to process general information 
to react appropriately to specific events;  
b)The product of communication, resulting from the 
collection, processing, integration, analysis, 
evaluation and interpretation of available 
information; c)Ability to acquire, store, retrieve, 
process and generate information; d) Ability to learn 
or understand or to deal with new or challenging 
situations; e) Accumulation of experiences together 
with the understanding of how these experiences 
are connected; f)Capacity to act purposefully, to 
think rationally, to communicate and to deal 
effectively with his or her environment.  
(g) Entity. (h) Emergent. 
Table 1. Definitions of Intelligence 
2.3.1 Intelligence = Informational entity 
By analyzing common traits within the definitions given in Table 1, intelligence may be 
defined as that emergent informational entity, capable of learning, exerting control, emitting 
and receiving communication, handling energy flows, establishing feedback mechanisms 
and creating organization for survival. Emergent implies a higher level of intelligence of the 
whole, stemming from the intelligence of its parts. According to Laszlo, living systems are 
special third-stage systems, self-creating and self-replicating, that engender order out of 
chaos (Lazlo, 1987). However, Wiener states ‘It is my thesis that the physical functioning of 
the living individual and the operation of some of the newer communications machines are 
precisely parallel in their analogous attempts to control entropy through feedback’ (Wiener, 
1954). The notion of intelligence that Olalde (2005) adopts is that of an informational entity, 
i.e. one which is emergent, can generate, process and exchange informational flows in order 
to control entropy. The concept of intelligence becomes more objective, and functional, 
when treated as an informational entity, one dependent on information exchange, which as 
we know has a thermodynamic interpretation. A change of entropy (S) will produce a 
change or variation in information availability, and therefore a change in intelligence and 
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order in the biological system. Any entity that can exchange informational flows can also 
generate changes of entropy. Thus, informational flow ņ change in entropy ņ change in 
intelligence. According to Stonier’s proposed theory ‘Pure energy can perform no ‘useful’ 
work (entropy reducing) without a concomitant input of information (Stonier, 1996). 
Conversely, all expenditures of energy lead to a reorganization of the universe, hence a 
change in its information status. Energy and information are inter-convertible’. This theory 
could provide additional support for the indispensable existence of an intelligent entity to 
handle information, since information without intelligence is without value. A possible 
corollary is: intelligence is that entity which can causatively alter entropy; and vice versa, 
entropy changes will also affect intelligence. Figure 4 shows an intelligent cell, an example 
of an informational entity capable of modifying entropy. 
 
 
Fig. 4. A living system possesses intelligence and is capable, as human cells demonstrate, of 
an informational flow and exchange with other cells, organs and living systems. This 
communicational flow may have various ‘vehicles’ and ‘avenues’. 
2.4 Synergy and informational systems  
Synergy is a quality of informational systems. It may be understood as emergent, i.e. the 
informational participation of each fractal member of the system in order to achieve a higher 
plateau of self-organization and survival (Haken, 2005). It can also be understood as the 
resulting effect that is greater than the algebraic sum of the parts. Synergy is an important 
characteristic of third-stage systems. The increase of energy availability within a third-stage, 
living, system also decreases its entropy, potentially generating an endogenous tendency for 
informational flow and a heightened intelligence; this in turn generates organization. By 
analogy, an increase of information will, on its own, raise intelligence which will positively 
influence energy and organization. In synergic terms, each of the three elements shown 
above has the capacity to affect (increase or decrease) the other two. Thus we derive the 
following synergic bi-conditionals, inherent to any third-stage system: survival potential = 
health = ↑Iņ↑Eņ↑OņSŅ and also demise = sickness = ŅI ņŅEņ ŅOņS↑. 
2.4.1 Informational substantiation of biological intelligence 
If there is communication, intelligence exists. Communication is a manifestation of 
intelligence. The existence of biochemical and bio-photonic communication in cells has been 
corroborated: biochemical communication, for example, between the neurological and 
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immune systems, has been examined, among others, by Blalock (1989), Cavagnaro and 
Lewis (1989) and more recently Takeda and Okomura (2004) and Cooper (2004). The 
biophotonic communication concept was discovered by Alexander Gurwitsch in 1923, as an 
‘ultraweak’ photon emission from living systems  (Gurwitsch, 1991). About the same time, 
Frolich, father of the ‘coherent’ notion of living systems, discovered that nucleated cells are 
capable of picking up, storing and broadcasting information about the environment. The 
term biophotons ‘…denotes a permanent spontaneous photon emission from all living 
systems…’ and explains ‘… biological phenomena like intracellular and intercellular 
communication, cell growth and differentiation, interactions among biological systems and 
microbial infections…’ (Popp, 2003). Different scientific groups have confirmed the existence 
of (and suggested some uses for) this subtle photon emission in: Australia (Tilbary & 
Quickenden, 1988; Trushin 2003), Japan (Kobayashi et al., 1996; Takeda et al., 1998), Poland 
(Slawinska & Slawinski, 1987) and Germany (Popp, 2003). Other prominent scientists in the 
study of biophotons are Professor Voeikov (Voikov, 2003) and Dr. Albrecht-Buehler. This 
last sustains the thesis that cells are intelligent: ‘capable of deriving abstract data and 
emitting near infrared signals’ (Albrecht-Buehler, 1998, 1985). 
2.4.2 Biological Intelligence (BI) 
Intelligence is best measured by its manifestations. In structural terms, the BI is 
‘omnipresent’ in the organism due to the intelligent nature of all cells (Gurwitsch, 1991); 
however, in functional terms, the BI’s common denominator is comprised of the immune 
intelligence (II), cellular intelligence (CI) and biochemical (or neuroendocrine) intelligence 
(BI) (Blalock, 1989; Cavagnaro and Lewis, 1989; Cooper, 2004; Takeda and Okomura, 2004). 
The BI functions as an emergent informational entity, oriented towards survival, capable of 
auto-regulation, bidirectional communication, generating, processing and manipulating 
energy flows within the body. It is in charge of establishing, maintaining and restituting the 
organization. Figure 5 shows the interaction between neuroendocrine, immune and cellular 
intelligence. CI is the most important of BI’s constituents since it regulates genetics and 
metabolism of each and every organic cell and gives birth to the autonomous II and BI. 
These three elements also constitute a synergistic trio, since none of them can exist in the 
absence of another, due to essential feedback and information exchange amongst them 
(Blalock, 1989; Cavagnaro and Lewis, 1989; Cooper, 2004; Takeda and Okomura, 2004). BI 
could also be represented schematically as a triangle, since alterations to one side of a 
triangle always affect the other two. Its healing potential may be defined as the 
mathematical product of its immune, cellular and neuroendocrine state, i.e. BI (Healing 
Potential) = II x CI x BI. In consequence, it is possible to enhance BI by increasing any of its 
three essential components, for example with immune modulators (Bocharova et al., 2003; 
Geng et al., 2005; Kidd, 2000; Kohguchi et al., 2004; Kormosh et al., 2004). The opposite also 
holds true, a collapse of any component will affect the other two.  
2.5 From Systemic theory to Systemic medicine 
At the beginning of this section a question was posed. Was it possible to set up a system -or 
periodic table- where plants and other natural remedies could, according to their superior 
medicinal properties, be arranged to produce specific formulae that provide well-being for a 
given pathology? The Systemic Theory was set forth to provide an answer to this crucial 
question. Systemic Theory postulates that Health (H) is directly proportional to the integrity 
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of a living system’s Energy (E), Bio-Intelligence (I) and Organization (O). Systemic Theory 
also established a common denominator to all sickness and ascertains the cause of all 
diseases to be an entropy increase: ‘disorder augmenting within the biologically open 
system, stemming from energo-informational and organizational impacts, either of external 
or internal nature’ (Olalde, 2005c). Systemic Therapeutics -or Medicine- should then include 
a negentropy supply to enhance the system’s: energy–work capacity or E (i.e. physiological 
mechanisms associated with ATP synthesis, such as oxidative phosphorolysis, Krebbs cycle, 
β-oxidation etc.), its informational potential intelligence or I (i.e. the entity responsible for 
regulating neuroendocrine, biochemical, immune and cellular processes) and finally 
structure and functional organization or O. Systemic Medicine’s (SM) treatment strategy is 
based on identifying and prescribing superior herbs—tonic or adaptogenic—or any 
nutraceuticals or medicine with potential to strengthen E, I, O by providing energo, 
informational and organizational aid to the overall network of intelligent cells and cell 
systems that constitute the body. The main premise proposes that when all three factors are 
brought back to ideal levels patients’ conditions begin recovery to normal health. Table 2 
provides a list of some E, I and O ceuticals -or superior medicines- whose capacity to 
enhance E, I and O have been studied and referenced.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. An example of known cross-talk communication, bidirectional and bi-conditional, 
between the II (immune intelligence), C I (cellular intelligence) and BI (biochemical or 
neuroendocrine intelligence) in a human living system. 
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E-Energoceuticals that 
enhance  
mitochondrial ATP 
synthesis and resynthesis 
I- Infoceuticals that enhance 
biointelligence on cellular, 
neuroendocrine and immune 
levels  
O-Organoceuticals that specifically 
enhance organ  
function and structure 
Names References Names References Names References 
Acantopanacis 
senticosus 
Wu et al. 
Gaffney et al.
Uncaria 
tomentosa 
Sheng et al ; 
Akesson et al. 
Glycyrrhiza glabra Acharya et al. 
Cornu Cervi 
pantotrichum 
Kim KS et al.
Zhang et al. 
Aloe vera Kim HS et al. Curcuma Longa Chainani-Wu 
Ilex 
paraguariensis 
Gorgen et al. 
Andrographis 
paniculata 
Matsuda et al ;
Puri et al. 
Ulmus fulva Brown et al. 
Lepidium 
meyenii 
Lopez-Fando 
et al. 
Astragalus 
membranaceus 
Wang et al ; 
Shao et al. 
Angelica sinensis Mei et al; Yin 
Ocimum 
sanctum 
Agrawal  
et al. 
Croton lechleri Risco et al. 
Chondroitin/ 
glucosamine 
Houpt et al. 
Panax 
ginseng 
Yang et al. 
Echinacea purpurea
and E. angustifolia 
Randolph et 
al., Cundell 
Chitin fiber Jing et al. 
Panax 
quinquefolius 
Wang et al. 
Ganoderma 
lucidum 
Kohguchi et 
al ; 
Jiang et al. 
Crataegus 
oxyacantha 
Rigelsky and Sweet ; 
Lacaille-Dubois et al. 
Pfaffia 
paniculata 
Kotsiuruba  
et al; 
Tashmukhame
dova et al. 
Grifola frondosa 
Odama et al ; 
Lin et al. 
Dioscorea villosa 
Shealy; 
Ladriere et al. 
Ptychopetalum 
olacoides 
Siqueira et al.
Hydrastis 
canadensis 
Rehman et al. Plants enzymes Popiela et al. 
Rhaponticum 
carthamoides 
Kutuzova  
et al. 
Morinda citrifolia Su et al. Equisetum arvense 
Blumenthal et al; 
Fleming 
Rhodiola 
rosea 
Maslova  
et al ; 
Spasov et al. 
Petiveria alliacea 
Ruffa et al; 
Malpezzi et al.
Ginkgo bilova 
Kubota et al ; 
Pepe et al. 
Schizandra 
chinensis 
Antoshechkin 
Sutherlandia 
frutescens 
Bence and 
Crooks; 
Jang et al. 
Gotu kola Incandela et al. 
l-arginine Gupta et al. 
Tabebuia 
avellaneda 
Planchon   
et al; Li et al. 
Sargassum fusiforme Ji et al. 
Ubiquinone 
(Coenzyme 
Q10) 
Baggio et al. 
Valeriana 
officinalis 
Dietz et al. 
Harpagophytum 
procumbens 
Chrubasik et al. 
  
Vitex agnus 
castus 
Kobayakawa 
and Sato-
Nishimori; 
Ohyama  
et al. 
Vitamins Carrero et al. 
  Lentinus edodes 
Borchers  
et al; Wasser 
and Weis 
Minerals Hercberg et al. 
  
Coriolus 
versicolor 
Sun and Zhu,  
Sun  
et al. 
Ptycopetalum 
olacoides 
Bucci; Siqueira et al. 
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E-Energoceuticals that 
enhance  
mitochondrial ATP 
synthesis and resynthesis 
I- Infoceuticals that enhance 
biointelligence on cellular, 
neuroendocrine and immune 
levels  
O-Organoceuticals that specifically 
enhance organ  
function and structure 
  
Cordyceps 
sinensis 
Leu et al. Pygeum africanum 
Freeman and 
Solomon, 
Santa Maria 
Margalef et al. 
    Rhamnus purshiana Ma et al. 
    Ruscus aculeatus 
Redman, Bouaziz et 
al.
    Salix alba Chrubasik et al. 
    Sena alejandrina Franz 
    Serenoa repens 
Goldmann et al ; 
Iguchi 
    Silibum marianum 
Halim et al; 
Chrungoo et al. 
    Smilax china Lee et al. 
    Tribulus terrestris Hong et al. 
    
Vaccinium 
myrthillus 
Zaragoza et al; 
Savickiene et al. 
    Viburnum spp. Calle et al. 
    Zingiber officinalis Young et al. 
Table 2. Examples of ceuticals -or superior medicines- whose capacity to enhance E, I and O 
has been studied and referenced 
2.5.1 The case for a systemic complex herbal formulation: Circulat 
Thus a composition was formulated taking into account the precepts established in both the 
Systemic Theory and Medicine. Circulat is a systemic standardized HPLC fingerprinted plant 
extract combination which consists of: 1) Energy plants (E) associated with ATP synthesis 
(such as tricarboxylic acid cycle, oxidative phosphorylation, etc) which boost the system’s 
energy-work capacity: Eleutherococcus senticosus, Leuzea carthamoides, Panax ginseng, Panax 
quinquefolius, Pfaffia paniculata, and Rhodiola rosea; 2) Bio-Intelligence plants (I) which modulate 
the neuroendocrine and immunological systems and cellular processes enhancing the system’s 
informational potential intelligence (specifically in this formulation they increase insulin 
production, insulin receptor sensitivity, improve intracellular glucose uptake, contribute anti-
microbial properties, improve inflammation as well as humoral and unspecific cellular 
immunity): Echinacea angustifolia, Echinacea purpurea, Ganoderma lucidum, Grifola frondosa, 
Hydrastis canadensis, Petiveria alliacea, Sutherlandia frutescens, and Uncaria tomentosa;  and finally 
3) Organizational plants (O) which enhance the structure and functional organization of 
specific organs supporting overall health (in Circulat’s case, among others, promoting 
vasodilatation, tissular perfusion improvement, regeneration and skin scarring): Angelica 
sinensis, Crataegus oxyacantha, Croton lechleri, Ginkgo biloba, Hydrocotyle asiatica, Ruscus aculeatus, 
Vaccinium myrthillus, and Tabebuia avellanedae. Although some of these plants act 
predominantly over one of the factors that influence individual’s overall health (E, I, and O), 
some act over more than one factor (i.e. Panax and Ganoderma). Please, see Table 3. 
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Energy plants  
Panax ginseng 
and  
Panax 
quinquefolius 
Increases ATP synthesis by stimulating activities of enzymes related to 
tricarboxylic acid cycle and oxidative-phosphorylation, such as succinate 
dehydrogenase, malate dehydrogenase, citrate synthetase, cytochrome oxidase, 
and phosphorylase (Wang et al;, 2003). 
Eleutherococcus 
senticosus 
Increases ATP synthesis by stimulating activities of enzymes related to 
tricarboxylic acid cycle, such as succinate dehydrogenase and malate 
dehydrogenase (Sugimura et al., 1989).  
Leuzea 
carthamoides  
and Pfaffia 
paniculata 
Increase ATP synthesis, stimulates activities of enzymes related to tricarboxylic 
acid cycle, such as succinate dehydrogenase. Also, normalize NADH 
dehydrogenase activity, enzyme related to the oxidative phosphorylation 
processes, contributing to buildup the electrochemical potential used to produce 
ATP (Tashmukhamedova et al., 1986). 
Rhodiola rosea 
Activates ATP synthesis/resynthesis in mitochondria, stimulates reparative 
energy processes (Abidov et al.; 2003). 
Anti-inflamatory-Inmunostimulant plants (Immune Intelligence) 
Tabebuia 
avellanedae 
Inhibits NO, iNOS, COX-2 and PGE(2) release. Attenuates expression of 
mRNA and pro-inflammatory cytokines proteins, such as interleukin (IL)-
1beta, IL-6 and tumor necrosis factor (TNF)-alpha. Suppresses NF-kappaB 
activation by blocking IkappaBalpha degradation and downregulating ERK, 
p38 mitogen-activated protein kinase (MAPK) and Akt pathway (Moon et al., 
2007).  
Echinacea 
angustifolia 
and Echinacea 
purpurea 
Due to: a) reduction of IL-2 production (Sasagawa et al., 2006); and b) down-
regulation of COX-2 expression (Groom et al, 2007). Immune-stimulant due 
to: a) macrophage phagocytosis stimulation (Raso et al., 2002); b) cellular 
immunity and neutrophils’ phagocytosis stimulation. Increases number of 
leucocytes and lymphocytes, especially T lymphocytes (Jurkstiene et al., 
2004); c) Significant enhancement of IgM specific antibody forming cell 
response (Freier et al., 2003); d) complement properdin increases (Kim et al.,   
2002). 
Ganoderma 
lucidum 
Promotes phagocytosis and cytotoxicity of macrophages (Zhu  et al., 2007). 
Grifola frondosa 
Antiinflamatory: because it inhibits cyclooxygenase (COX) enzyme (Zhang et al., 
2002). Inmunoestimulant because it: Increases IL-10, NO and IFN-gamma. 
Enhances both the innate and adaptive arms of the immune response (Kodama et 
al., 2004). 
Hydrastis 
canadensis 
Antiinflamatory due to a prostaglandin E2 production reduction as a result of 
AP-1 binding inhibition (Kuo  et al., 2004). 
Sutherlandia 
frutescens 
Antiinflamatory, inhibits COX-2 and through activation of activator protein-1 
(AP-1) (Kundu et al., 2005). 
Uncaria 
tomentosa 
Antiinflamatory achieved by a TNFalpha and PGE2 production inhibition 
(Piscoya et al., 2001).  
Inmunostimulant because it stimulates macrophage phagocytosis (Groom et al., 
2007).  
Panax ginseng 
and  
Panax 
quinquefolius 
Antiinflamatory: It inhibit iNOS and COX-2 protein expression, and activates the 
transcription factor, NF-kappaB (Park et al., 2004). Inmunomodulator: Increases 
neutrophiles and macrophages phagocytosis, stimulates humoral and cell 
immune factors and induces important regulating cytokins—interferone gamma 
and tumor necrosis factor (Smolina et al., 2001). 
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Eleutherococcus  
senticosus 
Inmunoestimulant: Activates B cells and macrophages (Han et al., 2003). 
Pfaffia paniculata Increases macrophage activity (Pinello et al., 2006) 
Angelica sinensis 
Immunomodulatory activity by regulating expression of Th1 and Th2 related 
cytokines (Yang et al., 2006). 
Hypoglycemic plants (Biochemical Intelligence) 
Panax ginseng 
Reduces blood glucose levels (Reay et al., 2005). Inhibits glycated hemoglobin 
formation (Bae and Lee, 2004). 
Panax 
quinquefolius 
Decreases postprandial glicemia (Vuksan et al., 2000) 
Eleutherococcus  
senticosus 
Lowers circulating glucose and lipids, and enhances insulin action (Park et al., 
2006).  
Improves insulin sensitivity (Liu et al., 2005). 
Ganoderma 
lucidum 
Stimulates glucose uptake, stimulating the activity of phosphatidylinositol 3-
kinase, Protein kinase B, AMP-activated protein kinase which are regulatory 
molecules in the glucose uptake pathway (Jung et al., 2006).  Lowers glucose 
levels through insulin-releasing activity due to facilitation of Ca2+ inflow to 
pancreatic beta cells (Zhang and Lin, 200 4). 
Grifola frondosa 
Decreases fasting plasma glucose levels and increases insulin sensitivity (Hong et 
al., 2007). 
Hydrastis 
canadensis 
Stimulates glucose uptake via: increasing GLUT1 activity and adenosine 
monophosphate-activated protein kinase and acetyl-coenzyme A carboxylase 
phosphorylation (Zhou et al., 2007); and through AMP-AMPK-p38 MAPK 
pathway (Cheng et al., 2006). Inhibitor of aldose reductase (Feng et al., 2005).  
Petiveria alliacea 
Decreases: a) blood glucose levels (Lores and Cires Puyol, 1990); and b) fasting 
glucose, post-prandial glucose levels, and hemoglobin A1c in type 2 diabetic 
patients, by acting downstream in the insulin signaling pathway (Kim et al., 
2007). 
Sutherlandia  
frutescens 
Normalizes insulin levels and increases glucose uptake (Chadwick et al., 2007). 
Decreases fasting glucose, post-prandial glucose levels, and hemoglobin A1c in 
type 2 diabetic patients, by acting downstream in the insulin signaling pathway 
(Kim et al., 2007).  
Antimicrobial and Skin Scarring  plants (Organization) 
Tabebuia  
avellanedae 
Antibacterial activity against methicillin-resistant S. aureus, S. epidermidis and 
S. haemolyticus strains, being the two last ones hetero-resistant to vancomycin 
(Pereira et al., 2006). 
Petiveria alliacea Broad spectrum of antimicrobial activity (Kim et al., 2006). 
Hydrastis 
canadensis 
Broad spectrum of antimicrobial activity (Scazzocchio et al., 2001). 
Sutherlandia 
frutescens 
Antibacterial against against S. aureus, E. faecalis and E. coli (Katerere and Elfo, 
2005). 
Uncaria 
tomentosa 
Antimicrobial activity on Enterobacteriaceae, S. mutans and Staphylococcus spp. 
(Ccahuana-Vasquez et al., 2007). 
Croton lechleri 
Potent anti-bacterial activity (Chen et al., 1994). Cicatrizant effect because it 
increases the migration of skin fibroblasts (Vaisberg et al., 1989).  
Hydrocotyle 
asiatica 
Promotes fibroblast proliferation and extracullar matrix synthesis in wound 
healing because it upregulates 54 genes with known functions for cell 
proliferation, cell-cycle progression and synthesis of the extracellular matrix (Lu 
et al., 2004). 
 
Table 3. Circulat´s E, I and O –referenced- components and action mechanisms.  
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3. Assessment of Circulat´s capability to modulate diabetes related gene 
expression levels in cultured human fibroblasts 
Circulat had provided an auspicious early clinical proof of its effectiveness (Olalde et al., 
2005) in the treatment of Diabetic Foot –a circulatory disease. However, a pending 
assignment was to confirm its molecular activity. One way to test this characteristic was to 
identify the modulating and/or synergistic roles that such formulation could have in 
diseases such as Diabetes Mellitus (I and II). The study called ‘Analysis of the Effects of the 
Herbal preparation Circulat on Gene Expression Levels in Cultured Human Fibroblasts’ was 
carried out in cooperation with the Pennsylvania State University, Department of Genetics 
(Antoshechkin et al., 2007). 
3.1 Materials and methods 
Circulat whole composition -a lyophilized ethanol/water extract of 22 known medical 
plants in different ratios- and its three E, I and O fractions (or components 1, 2 and 3) 
identical and in the same proportion as in the formula were tested using microarray 
analysis using the Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays that 
provide full genomic coverage and contain probes for more than 47 000 unique transcripts 
corresponding to more than 38 500 human genes. This allowed monitoring 
simultaneously the expression levels of practically all annotated genes of the human 
genome in an unbiased manner. Following hybridization and scanning, raw data in the 
form of image files were converted to gene expression files using the Affimetrix GeneChip 
Operating Software (GCOS) which utilizes MAS 5.0 algorithm for data normalization, 
background subtraction, and the estimation of nonspecific binding, calculation of 
detection p-values and generation of presence calls. Two-tailed Taylor Student’s t-test 
assuming unequal sample variance was used to identify genes that displayed significant 
changes in the mean expression levels between control and each of the treated samples 
with the t-test-p value less than 0.05 and the mean fold change of at least 2. By comparing 
up and down regulated genes in each individual fraction and whole Circulat, additional 
genes were identified that were regulated between 1.5 and 2 fold in the whole preparation 
and followed the same trend as in individual fractions, where they were up -or down- 
regulated by at least 2 fold.  
3.1.1 Results 
The Affymetrix GeneChip represents state of the art in microarray design and features 
both perfectly matched and off-by-one probes that together with sophisticated processing 
algorithm allow distinguishing precisely between specific and non-specific hybridization 
signals. It has been proven to produce highly reliable data, which in combination with the 
high quality of starting RNA and sufficient number of replicates virtually eliminates false-
positives. Significant changes in the mean expression levels between control and treated 
samples resulted in a list of 87, 96, 24 and 187 genes (probes) that were significantly up –
or down- regulated upon treatment with components 1, 2, 3 and whole Circulat, 
respectively. The genes regulated by the individual components and the whole Circulat 
formula showed a significant overlap, as expected. More than 80% of the genes affected 
by the individual fractions were also affected by the whole preparation. Analysis of the 
data for each of the three components also identifies a sizable number of genes (23) that 
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did not show up in the whole Circulat analysis. On the other hand, 55 genes the 
expression of which changed significantly after Circulat treatment were not observed in 
any of the three fractions. The regulation of these 32 genes by Circulat is more likely due 
to the interaction between active ingredients of the three components that produce a 
synergistic effect on gene regulation. Taken together the data demonstrates that: 1) 
Treatment of human fibroblast cells with either Circulat or its components result in 
marked changes in gene expression patterns; 2) Significant interactions between the active 
ingredients of Circulat exist resulting in a more complex pattern of gene expression in the 
complete preparation when compared with those of the isolated components which can 
be understood to be synergistic. Figure 6.  
 
 
Fig. 6. Circulat -as a whole- modulates 187 genes, 32 genes more than the sum of the E, I and 
O fractions that make it up. 
3.1.2 Analysis of processes and pathway affected by circulat 
Examination of the biological process subset of Gene Ontology (GO) terms (Ashburner et al., 
2000) associated with each gene and their distribution revealed that genes affected by 
Circulat are involved in a variety of cellular processes including protein, nucleic acid, lipid 
and carbohydrate metabolism, regulation of transcription, response to endogenous and 
external stimuli and stress, signal transduction and cell communication, cell growth and 
proliferation, development, protein modification and biosynthesis, generation of precursor 
metabolites and energy, etc. The broad spectrum of processes potentially regulated by 
Circulat (Figure 7) is consistent with the established ability of Circulat to prevent the 
development of severe manifestations of type 2 diabetes, which is a complex syndrome 
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involving many intracellular signaling cascades and pathways as well as cell-cell 
interactions.  
 
 
 
Fig. 7. Number of genes involved in a particular process that were affected by treatment is 
indicated. Numbers correspond to the number of probes that are annotated within a 
particular process.  
Many of those pathways are involved in energy generation and are regulated on both 
transcriptional and post-transcriptional levels in response to endogenous or exogenous 
stimuli. A high proportion of genes identified in the experiments are implicated in the 
regulation of transcription (e.g.ATF3, Kruppel-like factor 4 Zinc finger protein 117, 
SATB2), energy production and glucose metabolism (thioredoxin domain containing 11, 
ATP5F1, PGK1) and signal transduction corroborating the hypothesis that Circulat is 
capable of normalizing molecular processes perturbed in the course of type 2 diabetes. 
Specially, Circulat proves to be effective in the treatment of diabetic gangrene, which is 
often resistant to common treatments. Previous studies have suggested that impaired 
fibroblast function such as proliferation, cell migration, growth factor production and 
collagen synthesis may be part of the mechanism of diabetic necrotic damage. Fibroblasts 
are central to the processes of extracellular matrix deposition and remodeling that take 
place during tissue repair process. It functions both as a synthetic cell, depositing a 
collagen-rich matrix, and a signaling cell, secreting the growth factors important for cell-
cell communication during the tissue repair process. Many Circulat-regulated genes play 
roles in signal transduction and cell communication (ADAM32, TRIO, RAB7), response 
to endogenous and exogenous stimuli, an essential component in wound healing 
(FANCB, SLC19A2, C4A), growth factor-mediated signaling and cell motility (IL6, 
CXCL2, VIM), cell proliferation and biosynthesis (PBEF1, ABP1, PTGS2) corroborating 
Circulat’s effectiveness in tissue repair. Furthermore, tissue remodeling involves both the 
generation of new cell types as well as regulated cell death, and several genes important 
for cell differentiation and apoptosis were identified in the experiment (KLF4, RTN1, 
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PDCD5). It was also observed that significantly down-regulated genes are enriched for 
members of signaling cascades known to regulate transcription and progression through 
the mitotic cycle such as FOSB, SNF1-like kinase and PRKAR1A (cAMP-dependent 
protein kinase regulatory subunit), cyclin L2. Up-regulated genes also contain a high 
number of genes involved in progression through the cell cycle as well as in DNA 
damage response, including cyclin M. GTSE1, FANCB and BR1P1 (BRCA1 interacting 
protein C-terminal helicase 1), cyclin-dependent kinase inhibitor C2 (CDKN2C). A 
number of transcription factors and members of protein degradation machinery 
(ubiquitin-conjugating enzyme E2E 3, Ring finger and WD repeat domain 2) are also 
present among those genes. Data suggest that one of the reasons for Circulat’s 
therapeutic effects is derived from its ability to stimulate cellular activities that respond 
to internal and external stress by slowing or arresting the cell cycle to allow repair of 
cellular components that could be damaged in the course of the disease, such as DNA 
and proteins, to be carried out by repair enzymes.  
3.2 Discussion 
It was shown that four genes, IL6, HMGA1, SLC19A2 and C4A that are known to be 
involved in the development and progression of diabetes are strongly regulated by 
Circulat. This not only validated the experimental approach, but also allowed for the first 
time to suggest an explanation for the clinical effectiveness of Circulat at the molecular 
level. The role of interleukin-6 (1L6) in diabetes type 1 and 2 is thoroughly documented 
(for a review see Kristiansen and Mandrup-Poulsen, 2005). Low-grade inflammation has 
been proposed to be involved in the pathogenic processes causing type 2 diabetes and 
inflammatory mechanisms are known to play a key role in the pathogenesis of type 1 
diabetes. As a mediator of inflammation, IL6 is thought to be involved in events causing 
both types of the disease when present at elevated levels. In addition, IL6 can also 
regulate glucose homeostasis and metabolism directly and indirectly by both increasing 
the destruction of insulin producing β-cells by promoting apoptosis and playing a role in 
mounting insulin resistance in skeletal muscle, adipocytes and other tissues. Since 
elevated levels of IL6 are the known predisposition factors for development of diabetes, 
reduction of IL6 concentration should have the opposite therapeutic effect. The results 
demonstrate that Circulat treatment reduces IL6 expression more than two fold. (0.42, p 
=0.002) providing a solid link between the molecular events and the clinical 
manifestations taking place upon Circulat treatment. HMGA1 expression levels were 
elevated by more than two fold (2.07, p = 0.02) in samples treated with Circulat. 
Mutations in this small nuclear protein that acts as an architectural transcription factor 
have been detected in individuals suffering from type 2 diabetes (Foti et al., 2005). This 
correlated with the insulin receptor’s expression reduction and consequent development 
of insulin resistance. Deletion of HMGA1 gene in mice resulted in almost a complete loss 
of insulin receptor expression, development of insulin resistance and type 2 diabetes-like 
symptoms. HMGA1 thus plays a crucial role in glucose homeostasis and its increased 
expression promoted by Circulat may counteract deleterious effects caused by the loss of 
insulin receptor observed in type 2 diabetic patients. Two other genes, SLC19A2 and C4A, 
that are affected by Circulat (0.43, p = 0.03 and 0.48, p = 0.02, respectively) have also been 
unequivocally linked to diabetes. SLC19A2 encodes a thiamine transporter protein and 
causes thiamine-responsive megaloblastic anemia (TRMA) also known as Rogers 
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syndrome, when mutated (Labay et al., 1999). Diabetes (both type 1 and 2) is the primary 
disease that defines the syndrome. C4A encodes the acidic form of complement factor 4, 
part of the classical activation pathway. Deficiency of this protein is associated with 
systemic lupus erythematosus and type 1 diabetes mellitus (Palsdottir et al., 1983). While 
no direct link between C4A and diabetes type 2 has been found thus far, it has been 
suggested that the two types of the disease share many of the underlying processes thus 
making C4A involvement in type 2 diabetes a real possibility. Precise molecular 
mechanisms of SLC19A2 and C4A involvement in the disease development are not 
established as well as for IL6 and HMGA1. Nevertheless, their link to diabetes is 
indisputable and the ability of Circulat to influence their expression suggests additional 
possible Circulat action mechanisms. Analysis of genes affected by Circulat also reveals 
that 26 of them have been implicated in many human diseases other than diabetes. It is 
possible that some of those diseases and syndromes could be caused by misregulation of 
the same (or similar) genetic pathways that are perturbed in type 2 diabetes, which could 
be one of the explanations for this observation. On the other hand, it raises an exciting 
possibility that Circulat could be effective for treatment of conditions other than type 2 
diabetes. Finally, analysis of genes regulated by the total Circulat and its individual 
components demonstrated the existence of significant interactions between the active 
ingredients of Circulat suggesting that the full therapeutic effects can only be achieved by 
administration of the complete preparation.  
3.3 Significance of gene expression analyses 
The application of full-genome expression analyses to phytopharmacology opens new 
horizons for carrying out scientific studies of herbal remedies and integration of herbal-
based treatments into mainstream medicine. Using this approach, the physiologically active 
fractions of effective herbal extracts can be isolated and their specific activities can be 
determined. Such separation of different activities of a particular extract may enable 
researchers to selectively regulate the expression of specific genes (or gene groups) by 
varying the composition of the herbal preparation. It is likely therefore, that expression-
profiling-based approaches to studies of herbal medicines will become standard in 
phytopharmacology in the near future. This section, explained Circulat´s molecular 
modulating capabilities. Section 4 will examine its clinical effectiveness through a diabetic 
foot study synthesis. 
4. Circulat´s therapeutic properties in diabetic foot: Synthesis 
The World Health Organization estimated that more than 220 million people worldwide 
have diabetes (WHO, 2011). This number was likely to more than double by 2030. Diabetic 
foot ulcers are one of the most frequent complications of this disease. The prevalence of 
diabetic foot ulcers has been estimated, at the time of the study, between 2.2 and 15%. 
Differences being attributed to risk factor diversity: ethnicity, age, sex, education level, 
health service quality, and others (Table 4). Diabetic foot ulcers represent a large emotional 
and economic burden on patients and caregivers, as well (Gulam-Abbas et al, 2002). Foot 
complications are caused by diabetic neuropathy or peripheral ischemic vessel disease or a 
combination of both (Ratzmann et al, 1994) and are the most frequent reason for 
hospitalization in patients with diabetes. 
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Diabetic foot ulcers 
prevalence 
Country References 
2.2 % UK Abbott et al, 2002 
3-8% Sweden Apelqvist and Larsson, 2000 
4.6% Kenya Nyamu et al, 2003 
5.3-5.6% Finland Lehto et al, 1996 
5.4 - 7.3% USA Moss et al, 1996 
10.2% Sri Lanka Fernando, 1996 
15% Tanzania Gulam-Abbas et al, 2002 
Table 4. Examples of diabetic foot ulcer prevalence by country and references 
Diabetic foot complications are the most common cause of non-traumatic lower extremity 
amputations in the industrialized world. The risk of lower extremity amputation is 15 to 
46 times higher in diabetics than in persons who do not have diabetes mellitus 
(Armstrong, 1997). Approximately 40-60% of all lower extremity amputations are 
performed in patients with diabetes. More than 85% of these amputations are precipitated 
by a foot ulcer deteriorating to deep infection or gangrene (Apelqvist and Larsson, 2000). 
In people with healed diabetic foot ulcers, the 5 year cumulative rate of ulcer recurrence is 
66% and of amputation is 12% (Apelqvist et al., 1993). The high amputation incidence and 
healing failure after lower extremity amputation for the treatment of diabetic foot ulcer 
(Malay et al., 2006) is a distinct signal that the efficiency of conventional medical 
treatments used is less than optimal. This substantiates the need to search for effective 
therapeutic alternatives and diminish the suffering and high economic and social costs 
caused by this common diabetic patient complication. Various medicinal plants have been 
used traditionally for the treatment of circulatory obstructive diseases. In the last couple 
of decades many of their active principles and action mechanisms have been discovered. 
Also, traditional healing know-how has been proven to be effective in many cases. This 
raised the possibility of using herbal therapeutic protocols to complement conventional 
treatments for complications in diabetes. Specially, since there was mounting evidence 
which demonstrated that medicinal plants contained synergistic and/or side-effect 
neutralizing combinations (Thyagarajan et al., 2007; Gilani and Rahman, 2005). In contrast 
to synthetic pharmaceuticals based upon single chemicals, phytomedicines exert their 
beneficial effects through the additive or synergistic action of their multitude of 
constituents acting at single or multiple target sites (Dalby-Brown et al., 2005); because of 
their primary and secondary metabolite roles (Greenspan et al., 1994) and the adjuvant 
substances which enhance the activity of components actually responsible for the effect 
(Gilbert et al., 2003). In order to take the maximum advantage of the therapeutic 
properties as well as benefits of the synergistic action of the active principles in medicinal 
plants, it is necessary to use herbal combinations. Herbal formulations have been used for 
hundreds of years, however, little was known about the methodology to combine plants 
and obtain effective compositions. The Systemic Theory provided fundamentals which 
allowed the formulation of an effective herbal composition for treating diabetic foot 
(Olalde, 2005; Olalde et al., 2005). The previous section revealed that Circulat’s active 
principles exerted therapeutic effects through a synergistic action, as well as its potential 
for genetic normalization in diabetic patients (Antoshechkin et al., 2007). 
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4.1 Objective, research design and methods 
The aim was to appraise the clinical efficacy of Circulat in healing diabetic foot, measure the 
amputation rate and determine patient’s tolerance to the treatment. Thus, a retrospective, 
cohort, study of patients with type 2 diabetes and foot ulcerations from 50 medical centers, 
from 2004 to 2007. Patients were classified in accordance with The University of Texas 
Health Science Center Diabetic Wound Classification System (Lavery et al., 1997).  Patients 
were being administered ten Circulat  800 mg capsules twice per day, on an outpatient basis, 
during a period of two to four months. Each case was followed-up during a period of six 
months, after the end of the treatment. A patient was considered to attain clinical 
improvement if the lesion visibly decreased in size and depth, or closure or scarring of the 
wound was attained. All patients received conventional treatment for metabolism 
correction, local topic cures and systemic antibiotics. The Inclusion criteria of the study 
were: Patients of any age and gender diagnosed with Diabetes mellitus type 2, grades D1, 
D2 and D3 (University of Texas Diabetic Wound classification). 
4.1.1 Results and discussion 
The total number of patients which completed the treatment in accordance with the study’s 
inclusion criteria was 174. The mean was 61.3 years of age. The gender classification was: 
101 male (58.1%) and 73 female (41.9%). Clinical results are reflected in Table 5. 
Amputations were prevented in 88.55% (p< 0.00001, 99.9999%) of all 174 patients in the D1-
D3 categorization. The treatment was well tolerated; only 4 patients (2.3%) had minor 
gastrointestinal unrest which did not warrant treatment suspension. Conventional diabetic 
foot treatments, based on: risk factors control, affected area’s functional relaxation, 
metabolism correction, topical cures, antibiotics, rheology improving agents, prostanoid 
vasoactive therapy, platelet aggregation inhibitors, thrombolytic agents, tricyclic 
antidepressants or benzodiacepines for neuropathies and invasive treatments, such as 
endovascular, endarterectomy, by-pass or sympathectomy surgeries, do not manage to 
prevent small and large amputations which occur in 1.86 to 5.9 per every 1.000 diabetics per 
year (Bilenko et al, 2006; Winell et al, 2006; Rayman et al, 2004; Lavery et al, 2003; Trautner et 
al, 2001). Circulat- in combination with conventional therapy- prevented more amputations 
than various conventional treatments reported (Figure 8).  
 
University of Texas Diabetic 
Wound 
classification Grade 
N 
Total 
scarring 
Improvem
ent 
Total scarring 
+ 
Improvement 
Amputati
on 
D1: Infected ischemic superficial 
wounds, 
no tendon, capsule, or bone. 
88 
52  
(59.09%) 
36 
(40.9%) 
88/88  
(100%) 
- 
D2: Infected ischemic wounds, 
penetrating to tendon or capsule.
80 
 
32  
(40%) 
30 
(37.5%) 
62/80  
(77.5%) 
18/80  
(22.5%) 
D3: Infected ischemic wounds, 
penetrating to bone or joint. 
6 
 
4 
(66.6%) 
- 
4/6  
(66.6%) 
2/6  
(33.3%) 
Total 
174
 
88  
(50.57%) 
66 
(37.9%) 
154/174  
(88.5%) 
20/174  
(11.5%) 
 
Table 5. Results of Circulat treatment in Diabetic foot 
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Fig. 8. Examples of Diabetic Foot Amputation rates (%) in various countries 
5. Formulation´s potential in chronic ischemic heart disease treatment 
Context: The previous clinical study (Olalde et al., 2008) demonstrated a significant 
improvement in 174 diabetic foot patients. These encouraging outcomes and further 
evidence that other complex herbal formulations could help reduce atherosclerotic 
endothelium intima thickness (Tripathi et al., 2005) prompted us to evaluate the 
formulation by measuring the arterial intima-media thickness, a structural marker of 
early atherosclerosis that relates to the severity and extent of artery disease (Järvisalo et 
al., 2001), using high-resolution ultrasound (Celermajer et al., 1992). The study 
(unpublished) showed that treatment with this herbal combination significantly reduced 
the arterial intima-media thickness. These results further encouraged the formulation of 
a new hypothesis: could similar results be obtained in the treatment of IHD? If so, is 
there a potential for CAM complex herbal formulations’ intervention in the treatment of 
Ischemic Heart Disease?  Objective: Assess the hypothesis that myocardial perfusion, in 
chronic ischemic heart disease patients, might safely improve with Circulat. This was 
evaluated with Gated Single Photon Emission Computerized Tomography (GSPECT) 
imaging.  
5.1 Introduction 
Ischemic heart disease (IHD) is the leading cause of death -in both genders- worldwide 
and a major public health problem in the world. WHO (2009) has estimated this to be 7.2 
million deaths per year. IHD is the generic designation for a group of 
pathophysiologically related syndromes resulting from myocardial ischemia (an 
imbalance between supply -perfusion- and demand for oxygenated blood by the heart). 
IHD is caused by the atherosclerotic narrowing of one or more coronary arteries and 
endothelial dysfunction (Thadani, 2004, 2003, 1999). IHD brings oxygen insufficiency and 
reduces the availability of nutrients as well as the removal of metabolites. For this reason, 
IHD is generally less well tolerated by the heart than pure hypoxia, such as may be seen 
in severe anemia, cyanotic heart disease or advanced lung disease. Today much attention 
is being paid to Chronic Ischemic Heart Disease. This last is increasingly recognized as a 
dynamic condition. In addition to over acute myocardial infarction, which can precipitate 
at any time in patients with stable angina pectoris, clinical and sub-clinical ischemic 
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events may accumulate and in the long term generate diverse states of chronic cardiac 
dysfunction. Repetitive episodes of ischemia, whether stress induced or spontaneous, 
symptomatic or silent, may progressively impair myocardial contractile performance 
through myocardial stunning or hibernation, and eventually lead to left ventricular 
remodeling and heart failure. Evidence is accumulating that genetic variability and 
altered gene and protein expressions contribute to clinical outcomes in ischemic heart 
disease. Severe ischemic heart disease remains a clinical challenge; many patients have 
undergone myocardial revascularization procedures due to the extension and diffuseness 
of the disease. Also, viable options are becoming available for the ‘no option’ patients 
with chronic IHD. Instead of revascularization of the highly diseased epicardial coronary 
arteries, scientists and clinicians are looking –among other- at providing symptomatic 
relief in these patients via a biological bypass such as a ‘master’ cardiac stem cell for intra-
coronary and intra-myocardial injections (Bu et al., 2009). Current treatments include 
pharmacological agents such as nitrates, aspirin, beta-adrenoceptor antagonists and 
calcium channel blockers as well as invasive therapies aimed at restoring blood flow, e.g. 
coronary artery bypass graft (CABG) and improved percutaneous coronary intervention –
PCI (Tin-Hay et al., 2010). On the other hand, various medicinal plants are being used –
and researched- for the treatment of coronary heart disease and angina pectoris in China 
and East Asia, and are referenced in Chinese Materia Medica (Tam et al., 2009; Ling et al., 
2008; Duan et al., 2008; Zhao et al., 2007). This last does not preclude quite the contrary it 
demands, additional pharmacotherapy analysis and herbal medicines drug interaction 
research (Izzo et al., 2005). Nevertheless, the study and development for synthetic 
(Yamaguchi et al., 2009; Hirata et al., 2009) and medicinal plant in cardiac treatments 
continues (Chen et al., 2010; Luo et al., 2009).  
5.1.1 Study materials and methods  
Inclusion Criteria: Patients diagnosed with Chronic Ischemic Cardiopathy. Exclusion 
Criteria: Acute Coronary Syndrome, severe aortic valve stenosis, arrhythmia with 
hemodynamic repercussion, acute pericarditis, acute myocarditis, decompensated cardiac 
insufficiency, acute aortic syndrome, severe anemia, pulmonary embolism, severe arterial 
hypertension, severe pulmonary arterial hypertension, chronic debilitating diseases, 
second or third degree atrioventricular block, hypertrophic obstructive cardiomyopathy 
and valvular cardiomyopathy with hemodynamic compromise. Patients: 20 patients 
diagnosed with Chronic Ischemic Heart Disease were evaluated. Prior to treatment, tests 
had determined that 4 of these patients had cardiac ischemia, assessed with cardiac 
angiography and non invasive methods, and the other 9 patients tested positive for 
cardiac ischemia with the exercise treadmill testing protocol (Bruce). Initial cardiac 
ischemia diagnosis was also corroborated by GSPECT control imaging prior to treatment. 
Patients were receiving treatment with aspirin, ß-blockers, statins, nitrates, clopidogrel 
and anti-hypertensive medication (diuretics, ACE inhibitors, angiotensin II receptor 
antagonists, calcium channel blockers). Patients were given a complete physical 
examination at screening, each month and at the end of the treatment (sixth month). The 
patients’ baseline factors, relevant cardiac conditions and ongoing treatments were 
established in Table 6. The most pervasive baseline condition risk, evidenced from 
patients’ clinical history (Table 6) was Hypercholesterolemia (14/20; 70%). On the other 
hand, the most common treatment was aspirin (17/20; 85%).  
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Description 
Patient Number 
1 2 3 4 5 6 7 8 9
1
0
1
1
1
2
1
3
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
Gender M F M M M M M F M F F F M M F M F M M M
Age 68 
7
8
6
9
6
4
6
7
4
1
6
1
5
7
5
9
7
3
7
5
5
3
5
8
4
8 
6
6 
8
0 
6
7 
5
7 
5
9 
6
8 
Myocardial 
infarction 
N Y N Y N N N N Y Y N N N N Y Y Y Y Y Y 
CABG N N N N N N N N N N N N N N N Y N N N N 
PCI N N N N N N Y N N N N N N N N N N N N N 
Diabetes N N N N N Y N N N N N N N N N Y N N N Y 
Former 
smoker ≥ 30d N N N N N N N N Y N N N Y N Y N N N Y Y 
Hypertension N Y Y Y N N Y N Y Y N N N N Y Y Y N N Y 
Hypercholest-
erolemia 
Y Y N N Y Y N Y N Y N N Y Y Y Y Y Y Y Y 
BAA N N N N Y Y N Y Y N Y N N N Y N Y N N Y 
Statins N N Y Y N N Y N N Y N N N Y Y Y Y Y Y Y 
Aspirin Y N Y N Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Oral Anti-
diabetics 
N N N N N Y N N N N N N N N N Y N N N Y 
ACEI or ARB N N Y N N Y N N Y N Y N N N Y Y Y N N Y 
Ca2+-channel 
antagonist 
N N N N N N N N N N N N N N N N N N N N 
Diuretics N N N N N Y N N Y N Y N N N Y Y Y N N Y 
Legends. ACEI: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin -type I- 
Receptor Blocker; BAA: Beta Adrenoceptor Antagonists; CABG: Coronary Artery  
Bypass Graft;  d: days, Female: F; Male: M; N: No; PCI: Percutaneous Coronary 
Intervention.  
Y: Yes. All data determined from patients’ clinical histories. 
Table 6. Patients’ Baseline Characteristics 
Patients were instructed to receive ten 800 mg capsules b.i.d., of the herbal composition. 
Assessment of cardiac functions: The Bruce test, named after Dr. Robert A. Bruce, involves 
walking on a slanted treadmill while patient’s time resistance is measured and the heart is 
monitored by an electrocardiograph. Patients’ Pre -and Post- treatment, treadmill resistance 
time (Functional Capacity Time or FCT) were determined and reflected in Figure 9.  
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Note: Patients 2, 13, 15, 16 and 20 were unable to carry out the test due to physical limitations. 
Fig. 9. Pre  and Post (After) Treatment Functional Capacity Time  per patient  
5.2 Assessment of regional myocardial perfusion defect 
Patient’s -before and after Circulat treatment- post-effort -left ventricle- myocardial 
perfusion defect percentages were assessed by GSPECT imaging with technetium 99m-
tetrofosmin injection. This technique uses imaging procedures for detection with the help of 
gamma rays. In the procedure, the radioisotope is used on the patient and the gamma ray 
emitted by the technetium 99 that is in the radioisotope is captured on a special gamma 
camera. The total scanning time for the heart of a patient takes around twenty minutes 
which is enough time given the half life span of technetium 99. This isotope has a short half 
life –about six hours- and this small longevity is very useful for medical purposes. 
Recollection of data [imaging] is quick and the amount of radiation which a patient 
undergoes through is very low in intensity. GSPECT myocardial perfusion imaging is a 
widely used nuclear imaging procedure for diagnosis and management of coronary artery 
disease -which is the most common cause of heart failure. It is extensively available with 
superb standardization and reproducibility (Chen et al., 2008). For this study, the Phillips 
Forte (2007 model) AZ Spect Dual Headed Camera with an AUTOQUANT -quantitative 
algorithm- program for image processing was used. A 20 segment analysis was performed. 
Results of Perfusion Defect evolution are reflected in Figure 10. 
5.2.1 Results 
Clinical:  Patients’ Pre and Post Treatment Functional Capacity Time (treadmill evaluation) 
comparison (Figure 9) revealed that all patients who were physically capable to carry test 
out -except patient 17- improved their timed resistance [Female Improvement Median = 42.2 
sec; Male Improvement Median = 64.8 sec]. Finally, patients’ Post-Effort Left Ventricle 
Perfusion Defect imaging percentage values (Figure  10) were compared before and after six 
months treatment. Of the study group, 15 patients [75%] improved their perfusion defect. 
Statistics: The significance of the results was determined with the Wilcoxon Matched-Pairs 
Signed-Ranks Test (p ≤ 6.104 e-05; %=99.9999). All statistical data was determined using 
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SPSS 17.0 for Windows. Adverse events: No patients suffered any adverse events during the 
treatment.  
 
 
Fig. 10. Patient Cardiac Perfusion Defect Evolution (Ranked by age and gender) 
5.3 Discussion on ischemic heart treatment 
The results answered the formulated [raised] hypothesis. Indeed, CAM -and Circulat- can 
have a role in the treatment of Ischemic Chronic Heart Disease. This is supported by the 
number of patients (15 out of 20) which quantitatively improved their left ventricular 
perfusion capacity. Effects of this treatment are thought to be caused, among others, by 
vascular endothelium structure and function improvement, angiogenesis and tissue 
perfusion enhancement. Also to be noticed is patients’ disease evolution according to initial 
perfusion defect -reflected in Figure 10. There seems to be a correlation suggesting that 
initial stages of ischemia development -corresponding to lower Pre-Treatment perfusion 
defect- are more precociously responsive to a short (6 month) treatment, thus advocating  
use of the formulation as a preventive remedy against chronic ischemic heart disease. 
However, to measure the treatment’s potential effectiveness, in patients with acute 
perfusion defect, a longer lasting treatment -of at least one year is necessary. Just as 
pathologies -with critical conditions- warrant longer management periods.  
6. Conclusions on chapter 
A theory is as good as the praxis that backs it up. On one hand the gene expression study 
(Antoscheckin et al, 2007) established that a complex herbal formulation, designed in 
accordance with Systemic Theory precepts, had synergistic properties as well as the capacity 
to modulate genes implicated in diabetes development, energy metabolism, protein 
synthesis, glucose metabolism and signaling pathways. It also demonstarted that four genes 
(IL6, HMGA1, SLC19A2 and C4A) involved in the development and progression of diabetes 
are strongly regulated by Circulat. These bio-molecular results were confirmed with the 
further evaluation of diabetic foot management (Olalde et al., 2008) which provided clinical 
substantiation that a complex herbal formulation could be successful in providing 
therapeutic response to such a circulatory chronic disease. However, the result obtained in 
the reduction of perfusion defect in Chronic Ischemic patients was unexpected. It also 
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requires further validation. The authors are prolonging the length of the treatment –and the 
study- to one year. From this distance a better image of its potential therapeutic use can be 
assessed. However, there is room for cautious optimism. Evidence is accumulating that 
genetic variability and altered gene and protein expressions contribute to clinical outcomes 
in ischemic heart disease.  It is likely therefore, that expression-profiling-based approaches 
to chronic degenerative diseases such as diabetes and ischemic heart disease with herbal 
medicines will become standard in phytopharmacology in the very near future. Resuming: 
a)The confirmation of Circulat’s synergistic synergistic gene modulating capabilities (in 32 
genes, among which are four significant genes related to diabetes; b) The clinical outcomes 
of diabetic foot management which prevented the amputation of 88.5% of the study’s total 
population ; and c) The good response to therapy in 75% of the patients (p ≤ 6.104e-05; % = 
99.9999) by the composition in a GSPECT evaluated limited Phase II Chronic Ischemic Heart 
Disease suggest that treatment of circulatory pathologies with substances which act only on 
function and structure might be an incomplete approach. Whether the findings in 
circulatory chronic disease studies –and their results- can be generalized in confirming the 
systemic approach (E, I and O) is something that should be continued in medicinal science. 
Since this may pave the way for a new integral vision of therapeutics in general having 
started to proove its validity in circulatory chronic diseases in particular.  
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